Back to results
US 12,178,865 B2Granted
CDKN2A companion diagnostic for bladder cancer interferon therapy
AssigneeTrizell Ltd.
InventorColin P. Dinney
Life of this patent
Estimating the term…
Abstract
A method of treating bladder cancer comprising diagnosing bladder cancer in a human, measuring the human's level of CDKN2A expression, and then instilling into the human an agent which induces interferon expression.
Claims16
A method of treating Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer in a human, comprising:
- a. diagnosing Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer in a human,
- b. measuring a level of CDKN2A expression in a sample obtained from the human,
- c. selecting a human based on the level of CDKN2A expression measured in step b), and
- d. instilling into the lumen of the bladder of said human selected from step c) with a non-replicating vector comprising nadofaragene firadenovec.
1 more element
A method of treating Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer in a human, comprising:
- a. diagnosing Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer in a human,
- b. measuring a level of CDKN2A expression in an urine sample obtained from the human, wherein measuring the level of CDKN2A expression comprises analyzing exosomes or free DNA in the urine sample,
- c. selecting a human based on the level of CDKN2A expression measured in step b), and
- d. instilling into the lumen of the bladder of said human selecting in step c) with a non-replicating vector comprising nadofaragene firadenovec.
1 more element
Dependencies are inferred from the claim text.